SEC Form 4 · accession 0001171843-26-004082
HARVARD BIOSCIENCE INC · HBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine A. Eade
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 12, 2026 · 11:52 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001123494
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 9, 2026 | A | 16,556 | $0.00 | A | 58,669 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
- F2Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.
- F3On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.